Stelara and Fiasp/NovoLog. They accounted for $50.5 billion in total Part D covered prescription drug costs from June 2022 to May 2023, CMS said. The talks are set to take place later this year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback